Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07205159) titled 'A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata' on Sept. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Forte Biosciences, Inc.
Condition:
Alopecia Areata
Intervention:
Drug: FB102
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 15, 2025
Target Sample Size: 32
Countries of Recruitment:
Australia
New Zealand
Australia
New Zealand
To know more, visit https:/...